<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03390647</url>
  </required_header>
  <id_info>
    <org_study_id>E6130-CP2</org_study_id>
    <nct_id>NCT03390647</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Male Participants</brief_title>
  <official_title>A Phase 1 Clinical Study of E6130 - Clinical Pharmacology Study in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EA Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety, tolerability, and
      pharmacokinetics of multiple oral doses of E6130 in Japanese healthy adult male participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) as a measure of safety and tolerability</measure>
    <time_frame>Days 1 to 14 (Cohort A1); Days 1 to 12 (Cohorts A2 to A4); Days 1 to 8 (Cohort B1)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of E6130</measure>
    <time_frame>Days 1 to 4 and Days 7 to 10 (Cohort A1); Days 1 to 4 (Cohort B1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration at steady state (Css, max) of E6130</measure>
    <time_frame>Days 1 to 7 (Cohorts A2 to A4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (tmax) of E6130</measure>
    <time_frame>Days 1 to 4 and Days 7 to 10 (Cohort A1); Days 1 to 4 (Cohort B1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax at steady state (tss, max) of E6130</measure>
    <time_frame>Days 1 to 7 (Cohorts A2 to A4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from zero time to the time of last quantifiable concentration (AUC[0-t]) of E6130</measure>
    <time_frame>Days 1 to 4 and Days 7 to 10 (Cohort A1); Days 1 to 4 (Cohort B1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from zero time extrapolated to infinite time (AUC[0-inf]) of E6130</measure>
    <time_frame>Days 1 to 4 and Days 7 to 10 (Cohort A1); Days 1 to 4 (Cohort B1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentration-time curve from zero time to 24 hours (AUC[0-24h]) of E6130</measure>
    <time_frame>Days 1 to 7 (Cohorts A2 to A4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination phase half-life (t1/2) of E6130</measure>
    <time_frame>Days 1 to 7 (Cohorts A2 to A4)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese participants will receive a single oral dose of E6130 on Day 1 and Day 7 administered in the specified order (fasted/fed or fed/fasted) to evaluate the food effect.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caucasian participants will receive a single oral dose of either E6130 or placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohorts A2-A4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Japanese participants will receive multiple oral doses of E6130 or placebo on Days 1 to 5, administered in a randomized, dose-ascending manner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E6130</intervention_name>
    <description>Oral dose</description>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_label>Cohorts A2-A4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>E6130-matched placebo</description>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_label>Cohorts A2-A4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants must meet all of the following criteria to be included in this study.

          1. Japanese or Caucasian healthy adult males aged â‰¥20 and &lt;45 years at the time of
             informed consent who are non-smokers or able to stop smoking from at least 4 weeks
             before study drug administration until the post-treatment examination

          2. Has voluntarily consented, in writing, to participate in this study

          3. Has been thoroughly briefed on the conditions for participation in the study, and are
             willing and able to comply with the conditions

        Exclusion Criteria:

        Participants who meet any of the following criteria will be excluded from this study.

          1. History of surgical treatment may affect the pharmacokinetics of the study drug at
             screening

          2. Suspected to have clinically abnormal symptoms or impairment of organ function
             requiring treatment on the basis of history and complications at screening, and
             physical findings, vital signs, electrocardiogram findings, or laboratory values at
             screening or baseline

          3. History of drug allergy at screening

          4. Judged by the investigator or sub investigator to be inappropriate for participation
             in this study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Public Relations Group</last_name>
    <phone>+81-(0)3-6280-9600</phone>
    <email>contact_ea@eapharma.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>EA Pharma Trial Site</name>
      <address>
        <city>Sumida</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2017</study_first_submitted>
  <study_first_submitted_qc>December 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>December 28, 2017</last_update_submitted>
  <last_update_submitted_qc>December 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E6130</keyword>
  <keyword>Healthy adult male participants</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

